Those include lower risk of 10 cancers, protection against heart and kidney diseases, and reduction in systemic inflammation, according to recently published research.

Pending a decision from the European Commission, Ozempic® (once-weekly semaglutide) will have the broadest approved label in the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class ...

New research suggests, Ozempic might now support heart health, decreasing the likelihood of cardiac events even without type-2 diabetes. Doctor shares insights on the topic.

Pending a decision from the European Commission, Ozempic® (once-weekly semaglutide) will have the broadest approved label in the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class, ...

Novo Nordisk, a leading global healthcare company, announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an ...

The Hidden Downsides of Doorbell Cameras—and What to Do About Them Man who came to US as young child faces deportation after over 30 years I Built a 1500HP Big Block Mustang for Burnouts ...

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities ...

Vaccinated patients hospitalized with COVID-19 who developed acute kidney injury had better outcomes than unvaccinated patients with the same condition, new research suggests. The study found ...

Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure increasing danger of macular degeneration.

Pending a decision from the European Commission, Ozempic ® (once-weekly semaglutide) will have the broadest approved label in the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class, ...

Ozempic improved walking distance in patients with type 2 diabetes and early peripheral artery disease, regardless of baseline diabetes characteristics.